This “Whooping cough - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Whooping cough pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Whooping cough Understanding
Whooping cough, also known as pertussis, is a highly contagious respiratory disease. It is known for uncontrollable, violent coughing which often makes it hard to breathe. Pertussis may start with symptoms that mimic common cold such as cough, common cold, and fever. Within the span of two weeks, a persistent and dry cough may develop which may hinder normal breathing of an individual. The diagnosis of Pertussis is done by conducting a chest X-ray, a nose or throat culture and examination, and blood tests. Macrolide antibiotics such as azithromycin are first-line treatments to prevent transmission; trimethoprim/sulfamethoxazole is an alternative in cases of allergy or intolerance to macrolides. Immunization against pertussis is essential for disease prevention. Secondary bacterial pneumonia is the most common complication of whooping cough.
"Whooping cough - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Whooping cough pipeline landscape is provided which includes the disease overview and Whooping cough treatment guidelines. The assessment part of the report embraces, in depth Whooping cough commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Whooping cough collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Whooping cough R&D. The therapies under development are focused on novel approaches to treat/improve Whooping cough.
This segment of the Whooping cough report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
GC Pharma's drug candidate GC3111A is being developed as a vaccine against Diphtheria, Pertussis, and Tetanus. The drug belongs to the class of bacterial vaccines and work as immunostimulants. GC3111A is in Phase II clinical studies for the treatment of diphtheria, pertussis, and tetanus.
TdaP is a tetanus-reduced diphtheria-acellular pertussis vaccine. It contains tetanus and diphtheria toxoids and acellular pertussis antigens. The drug is in Phase III clinical studies for the treatment of diphtheria, pertussis, and tetanus.
This segment of the report provides insights about the different Whooping cough drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the therapies for Whooping cough. The companies which have their Whooping cough drug candidates in the most advanced stage, i.e. Phase III include, BioNet-Asia.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Whooping cough therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Whooping cough drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Whooping cough Understanding
Whooping cough: Overview
Whooping cough, also known as pertussis, is a highly contagious respiratory disease. It is known for uncontrollable, violent coughing which often makes it hard to breathe. Pertussis may start with symptoms that mimic common cold such as cough, common cold, and fever. Within the span of two weeks, a persistent and dry cough may develop which may hinder normal breathing of an individual. The diagnosis of Pertussis is done by conducting a chest X-ray, a nose or throat culture and examination, and blood tests. Macrolide antibiotics such as azithromycin are first-line treatments to prevent transmission; trimethoprim/sulfamethoxazole is an alternative in cases of allergy or intolerance to macrolides. Immunization against pertussis is essential for disease prevention. Secondary bacterial pneumonia is the most common complication of whooping cough.
"Whooping cough - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Whooping cough pipeline landscape is provided which includes the disease overview and Whooping cough treatment guidelines. The assessment part of the report embraces, in depth Whooping cough commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Whooping cough collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Whooping cough R&D. The therapies under development are focused on novel approaches to treat/improve Whooping cough.
Whooping cough Emerging Drugs Chapters
This segment of the Whooping cough report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Whooping cough Emerging Drugs
GC3111A: Green Cross
GC Pharma's drug candidate GC3111A is being developed as a vaccine against Diphtheria, Pertussis, and Tetanus. The drug belongs to the class of bacterial vaccines and work as immunostimulants. GC3111A is in Phase II clinical studies for the treatment of diphtheria, pertussis, and tetanus.
TdaP: BioNet-Asia
TdaP is a tetanus-reduced diphtheria-acellular pertussis vaccine. It contains tetanus and diphtheria toxoids and acellular pertussis antigens. The drug is in Phase III clinical studies for the treatment of diphtheria, pertussis, and tetanus.
Whooping cough: Therapeutic Assessment
This segment of the report provides insights about the different Whooping cough drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Whooping cough
There are approx. 10+ key companies which are developing the therapies for Whooping cough. The companies which have their Whooping cough drug candidates in the most advanced stage, i.e. Phase III include, BioNet-Asia.
Phases
This report covers around 12+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Whooping cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Whooping cough: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Whooping cough therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Whooping cough drugs.
Whooping cough Report Insights
- Whooping cough Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Whooping cough Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Whooping cough drugs?
- How many Whooping cough drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Whooping cough?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Whooping cough therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Whooping cough and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- KM Biologics
- Serum Institute of India
- BioNet-Asia
- Dynavax Technologies
- Biological E Limited
- Tianjin CanSino Biotechnology
- Faron Pharmaceuticals
Key Products
- KD-370
- DTaP vaccine
- DTwP-HepB-IPV-Hib vaccine
- SIIPL Tdap IPV
- TdaP
- Adjuvanted pertussis vaccine
- DTwP Hib vaccine
- DTcP vaccine (infant)
- Bexmarilimab
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Whooping cough: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Whooping cough - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
KD-370: KM Biologics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
DTaP vaccine: Serum Institute of India
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
SIIPL Tdap IPV: Serum Institute of India
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
Bexmarilimab: Faron Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Whooping cough Key Companies
Whooping cough Key Products
Whooping cough- Unmet Needs
Whooping cough- Market Drivers and Barriers
Whooping cough- Future Perspectives and Conclusion
Whooping cough Analyst Views
AppendixList of Tables
Table 1 Total Products for Whooping cough
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Whooping cough
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- KM Biologics
- Serum Institute of India
- BioNet-Asia
- Dynavax Technologies
- Biological E Limited
- Tianjin CanSino Biotechnology
- Faron Pharmaceuticals
